Inhaled Cannabis for Treatment of PTSD

The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.

NCT Number	NCT07224698
Lead Sponsor	Multidisciplinary Association for Psychedelic Studies Collaborators: Changemark Research + Evaluation Ltd.
Conditions	Post Traumatic Stress Disorder PTSD
Enrollment	320 participants
Start Date	2027-02
Primary Completion	2028-10 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-11